AB
AMC Bio develops novel, first-in-class diagnostics and therapeutics targeting emerging RNA viral pathogens. The company is advancing a Long COVID diagnostic alongside preclinical programs utilizing synthetic peptides and bacterial polypeptides effective against Dengue and other significant RNA viruses. This work addresses the current lack of science-backed tests and therapeutic treatments for conditions like Long COVID and Dengue Fever.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- AMC Bio develops novel, first-in-class diagnostics and therapeutics targeting emerging RNA viral pathogens. The company is advancing a Long COVID diagnostic alongside preclinical programs utilizing synthetic peptides and bacterial polypeptides effective against Dengue and other significant RNA viruses. This work addresses the current lack of science-backed tests and therapeutic treatments for conditions like Long COVID and Dengue Fever.